These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23975704)

  • 1. Clinical and economic implications of the use of nanoparticle paclitaxel (Nanoxel) in India.
    Ranade AA; Joshi DA; Phadke GK; Patil PP; Kasbekar RB; Apte TG; Dasare RR; Mengde SD; Parikh PM; Bhattacharyya GS; Lopes GL
    Ann Oncol; 2013 Sep; 24 Suppl 5():v6-12. PubMed ID: 23975704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficiency and mechanism of intracellular paclitaxel delivery by novel nanopolymer-based tumor-targeted delivery system, Nanoxel(TM).
    Madaan A; Singh P; Awasthi A; Verma R; Singh AT; Jaggi M; Mishra SK; Kulkarni S; Kulkarni H
    Clin Transl Oncol; 2013 Jan; 15(1):26-32. PubMed ID: 22855169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse drug reaction profile of nanoparticle versus conventional formulation of paclitaxel: An observational study.
    Brahmachari B; Hazra A; Majumdar A
    Indian J Pharmacol; 2011 Apr; 43(2):126-30. PubMed ID: 21572644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in India.
    Lopes Gde L
    Ann Oncol; 2013 Sep; 24 Suppl 5():v13-6. PubMed ID: 23975699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I dose escalation and pharmacokinetic study on the nanoparticle formulation of polymeric micellar paclitaxel for injection in patients with advanced solid malignancies.
    Shi M; Sun J; Zhou J; Yu H; Yu S; Xia G; Wang L; Teng Y; Liu G; Yu C; Feng J; Shen Y
    Invest New Drugs; 2018 Apr; 36(2):269-277. PubMed ID: 28868573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter phase II randomized study of Cremophor-free polymeric nanoparticle formulation of paclitaxel in women with locally advanced and/or metastatic breast cancer after failure of anthracycline.
    Ranade AA; Bapsy PP; Nag S; Raghunadharao D; Raina V; Advani SH; Patil S; Maru A; Gangadharan VP; Goswami C; Sekhon JS; Sambasivaiah K; Parikh P; Bakshi A; Mohapatra R
    Asia Pac J Clin Oncol; 2013 Jun; 9(2):176-81. PubMed ID: 23176568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
    Ibrahim NK; Desai N; Legha S; Soon-Shiong P; Theriault RL; Rivera E; Esmaeli B; Ring SE; Bedikian A; Hortobagyi GN; Ellerhorst JA
    Clin Cancer Res; 2002 May; 8(5):1038-44. PubMed ID: 12006516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
    Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
    Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and cost-effectiveness of paclitaxel administered as a 1-hour infusion versus a 3-hour infusion for various malignancies.
    Gammon DC; Lizotte MW
    J Infus Nurs; 2004; 27(4):251-3. PubMed ID: 15273632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
    Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
    Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
    Dranitsaris G; Coleman R; Gradishar W
    Breast Cancer Res Treat; 2010 Feb; 119(3):717-24. PubMed ID: 19495958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM™ using polymer-based delivery system.
    Lee SW; Yun MH; Jeong SW; In CH; Kim JY; Seo MH; Pai CM; Kim SO
    J Control Release; 2011 Oct; 155(2):262-71. PubMed ID: 21704664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain.
    Alba E; Ciruelos E; López R; López-Vega JM; Lluch A; Martín M; Muñoz M; Sánchez-Rovira P; Seguí MÁ; Liria MR; Pérez-Alcántara F
    Expert Rev Pharmacoecon Outcomes Res; 2013 Jun; 13(3):381-91. PubMed ID: 23534988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.
    Montero AJ; Avancha K; Glück S; Lopes G
    Breast Cancer Res Treat; 2012 Apr; 132(2):747-51. PubMed ID: 22200867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [nab-Paclitaxel. Clinical value of an innovative taxane-containing formulation].
    Lipp HP
    Med Monatsschr Pharm; 2013 Jan; 36(1):14-24. PubMed ID: 23379109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
    Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A
    Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study.
    Ko YJ; Canil CM; Mukherjee SD; Winquist E; Elser C; Eisen A; Reaume MN; Zhang L; Sridhar SS
    Lancet Oncol; 2013 Jul; 14(8):769-76. PubMed ID: 23706985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel.
    Rischin D; Webster LK; Millward MJ; Linahan BM; Toner GC; Woollett AM; Morton CG; Bishop JF
    J Natl Cancer Inst; 1996 Sep; 88(18):1297-301. PubMed ID: 8797769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.